IMUX
NASDAQ HealthcareImmunic, Inc. - Common Stock
Biotechnology
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
๐ Market Data
| Price | $9.65 |
|---|---|
| Volume | 173,943 |
| Market Cap | 131.45M |
| Beta | 1.370 |
| RSI (14-Day) | 31.4 |
| 200-Day MA | $8.63 |
| 50-Day MA | $11.03 |
| 52-Week High | $15.10 |
| 52-Week Low | $5.06 |
| Forward P/E | -3.06 |
| Price / Book | -17.42 |
๐ฏ Investment Strategy Scores
IMUX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (89/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ Institutional Whale (2/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find IMUX in your text
Paste any article, transcript, or post โ the tool will extract IMUX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.